» Articles » PMID: 34012303

Contentious Issues in Gout Management: The Story So Far

Overview
Publisher Dove Medical Press
Specialty Rheumatology
Date 2021 May 20
PMID 34012303
Authors
Affiliations
Soon will be listed here.
Abstract

Gout is the most common inflammatory arthritis worldwide. Although gout has been known for antiquity, many challenges still exist in gout management. It is vital to view gout as a chronic disease and not just treat the acute flare. There is a perception of gout as an acute disease requiring treatment only for acute flares. However, to combat the disease, chronic urate-lowering therapy, reducing the serum urate levels to below the saturation threshold of 6.8 mg/dL, and chronic anti-inflammatory prophylaxis, especially during urate-lowering therapy initiation, are needed. In this manuscript, we discuss some of the contentious issues in gout management. These include the timing of urate-lowering therapy initiation, which urate-lowering therapy to chose, should comorbidities influence our treatment, using genetic determinants, and patient perspectives to drive treatment and differences between gout treatment the American College of Physicians and Rheumatology guidelines for gout management: driving care.

Citing Articles

Current Status of Gout Arthritis: Current Approaches to Gout Arthritis Treatment: Nanoparticles Delivery Systems Approach.

Herdiana Y, Wardhana Y, Kurniawansyah I, Gozali D, Wathoni N, Sofian F Pharmaceutics. 2025; 17(1).

PMID: 39861750 PMC: 11768112. DOI: 10.3390/pharmaceutics17010102.

References
1.
Ke C, Chung W, Wen Y, Huang Y, Chuang H, Tain Y . Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions. J Rheumatol. 2017; 44(6):835-843. DOI: 10.3899/jrheum.151476. View

2.
Fralick M, Chen S, Patorno E, Kim S . Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med. 2020; 172(3):186-194. PMC: 7217750. DOI: 10.7326/M19-2610. View

3.
MASBERNARD A, Giudicelli C . Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med J. 1981; 59(20):701-6. View

4.
Gonzalez-Galarza F, Takeshita L, Santos E, Kempson F, Maia M, da Silva A . Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 2014; 43(Database issue):D784-8. PMC: 4383964. DOI: 10.1093/nar/gku1166. View

5.
Sarawate C, Patel P, Schumacher H, Yang W, Brewer K, Bakst A . Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006; 12(2):61-5. DOI: 10.1097/01.rhu.0000209882.50228.9f. View